---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000023"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:34:07.039050+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks

## Summary
- Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).
- Cash $561.5M after $216M stock offering and $23M milestone to Ligand for FILSPARI approval.
- FILSPARI launched week of Feb 27; 146 new patient start forms received in first 6 weeks.
- Phase 3 DUPLEX in FSGS missed primary eGFR slope endpoint; company to engage regulators on path forward.
- EMA decision on sparsentan for IgAN expected H2 2023; PROTECT confirmatory data due Q4 2023.

## SEC filing metadata
- accession: 0001438533-23-000023
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/tvtx-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000023
- JSON: https://secwatch.observer/filing/0001438533-23-000023.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000023.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $57.0 million, net income $86.3 million, EPS $1.27 per basic share.
  - Period: the quarter ended March 31, 2023
  - Revenue: $57.0 million
  - Net income: $86.3 million
  - EPS: $1.27 per basic share
  - Result: reported results
  source text: IgAN in Europe expected in second half 2023 • Net product sales of FILSPARI totaled $3.0 million for the first quarter of 2023 • Total revenue for the first quarter of 2023 was $57.0 million, consisting of $50.3 million in net product sales and $6.7 million in licensing and collaboration revenue • Cash, cash equivalents, and marketable securities, as of March 31,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.